Companies › ALX Oncology
2 active drug programs in 9 registered trials: 6 Phase 2, 3 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Evorpacept (ALX148) Leukocyte surface antigen CD47 inhibitor | CD47 | Phase 2 | Gastric Cancer; Head and Neck Cancer; Breast Cancer, Metastatic; Ovarian Cancer … | Dec 2027 |
| ALX2004 anti-EGFR antibody-drug conjugate | EGFR | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05002127 | Evorpacept (ALX148) | Phase 2 | Gastric Cancer | Oncology | May 2024 |
| NCT04675333 | Evorpacept (ALX148) | Phase 2 | Head and Neck Cancer | Oncology | Mar 2025 |
| NCT04675294 | Evorpacept (ALX148) | Phase 2 | Head and Neck Cancer | Oncology | Mar 2025 |
| NCT07085091 | ALX2004 | Phase 1 | NSCLC (Advanced Non-small Cell Lung Cancer) | Oncology | Jun 2027 |
| NCT07007559 | Evorpacept (ALX148) | Phase 2 | Breast Cancer, Metastatic | Oncology | Dec 2027 |
| NCT05025800 | Evorpacept (ALX148) | Phase 1 | Aggressive B-Cell Non-Hodgkin Lymphoma | Oncology | Mar 2028 |
| NCT05467670 | Evorpacept (ALX148) | Phase 2 | Ovarian Cancer | Oncology | Apr 2029 |
| NCT05787639 | Evorpacept (ALX148) | Phase 2 | Oropharynx Cancer | Oncology | Oct 2029 |
| NCT05868226 | Evorpacept (ALX148) | Phase 1 | HER2-positive Breast Cancer | Oncology | Dec 2030 |
Cash and short-term investments of $138m on 2026-06-30; operating cash outflow about $70m a year; runway about 24 months at that burn, to Jun 2028; 1 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
ArriVent BioPharma Eikon Therapeutics Kura Oncology Lyell Immunopharma Black Diamond Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.